10-KPeriod: FY2009

ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2009

Filed February 26, 2010For Securities:ALNY

Summary

This 10-K filing for Alnylam Pharmaceuticals, Inc. as of December 31, 2009, highlights a company in the developmental stages of its business, heavily focused on the research and development of RNA interference (RNAi) therapeutics. While the company has no products on the market, it has established a robust pipeline of investigational drugs targeting various genetic diseases. The filing emphasizes significant investments in R&D, a key indicator for biotechnology firms, and outlines potential risks associated with drug development, regulatory approvals, and market adoption. Financially, Alnylam's operations are characterized by substantial research and development expenses, leading to net losses, which is typical for companies in this sector. The company relies on collaborations and strategic partnerships to advance its pipeline and fund its operations. Investors should pay close attention to the company's cash runway, its progress in clinical trials, and its ability to secure future funding and commercialize its innovative therapies. The lack of current revenue streams means that future growth is entirely contingent on the successful development and launch of its drug candidates.

Financial Highlights

41 data points
Beta

Revenue

$100.53M

Net Income

-$47.59M

-47.3% Net Margin

EPS (Diluted)

$-1.14

Total Assets

$481.38M

Cash & Equivalents

$137.47M

Free Cash Flow

-$77.09M

Financial Statements
Beta
Revenue$100.53M
R&D Expenses$108.73M
Operating Expenses$148.64M
Operating Income-$48.11M
Net Income-$47.59M
EPS (Basic)$-1.14

Key Highlights

  • 1Alnylam Pharmaceuticals is focused on developing RNA interference (RNAi) therapeutics, a novel approach to gene silencing.
  • 2The company has a significant pipeline of investigational drugs in various stages of clinical development, targeting a range of rare genetic diseases.
  • 3Substantial investment in Research and Development (R&D) is a core driver of the company's operations and future potential.
  • 4Alnylam has entered into strategic collaborations and licensing agreements to advance its pipeline and secure funding.
  • 5The company reported net losses, consistent with its R&D-intensive business model and lack of commercialized products.
  • 6Key risk factors include the inherent uncertainties of drug development, clinical trial success, regulatory approvals, and market acceptance of novel therapies.

Frequently Asked Questions

Alnylam Pharmaceuticals is primarily focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, which aim to treat diseases by silencing specific genes.

As of the filing date (December 31, 2009), Alnylam Pharmaceuticals did not have any approved products on the market. Its business model is centered on its R&D pipeline.

Alnylam funds its R&D through a combination of its own capital (cash and investments), strategic collaborations, licensing agreements, and potentially through equity financing. The filing details several key partnerships.

The primary risks for Alnylam include the high failure rate inherent in drug development, the need for successful clinical trial outcomes, obtaining regulatory approvals, competition from other pharmaceutical companies, intellectual property challenges, and the potential inability to secure sufficient funding to bring its therapies to market.